Ursolic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 3, 2013, Pages 723-730

  Shin, Seoung Woo ^a   Park, Jeen Woo ^a  

^a Kyungpook National University   (South Korea)

Author keywords

Apoptosis; DR5; Prostate cancer; TRAIL; Ursolic acid

Indexed keywords

CASPASE 3; DEATH RECEPTOR 5; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INHIBITOR OF APOPTOSIS PROTEIN 1; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; URSOLIC ACID; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; MALE; OXIDATION-REDUCTION; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR CHOP; TRITERPENES; TUMOR CELLS, CULTURED;

EID: 84872043201     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.12.005     Document Type: Article

References (42)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010, 60:277-300.
2. Hayat M.J., Howlader N., Reichman M.E., Edwards B.K. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007, 12:20-37.
3. Long R.J., Roberts K.P., Wilson M.J., Ercole C.J., Pryor J.L. Prostate cancer: a clinical and basic science review. J. Androl. 1997, 18:15-20.
4. Petrylak D.P. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1997, 54:30-35.
5. Pisters L.L. The challenge of locally advanced prostate cancer. Semin. Oncol. 1999, 26:202-216.
6. Richie J.P. Anti-androgens and other hormonal therapies for prostate cancer. Urology 1999, 54:15-18.
7. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996, 271:12687-12690.
8. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 2003, 3:745-756.
9. Bellail A.C., Tse M.C., Song J.H., Phuphanich S., Olson J.J., Sun S.Y., Hao C. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J. Cell. Mol. Med. 2010, 14:1303-1317.
10. Deeb D., Jiang H., Gao X., Hafner M.S., Wong H., Divine G., Chapman R.A., Dulchavsky S.A., Gautam S.C. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol. Cancer Ther. 2004, 3:803-812.
11. Yamaguchi K., Uzzo R.G., Pimkina J., Makhov P., Golovine K., Crispen P., Kolenko V.M. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005, 24:5868-5877.
12. Hu H., Jiang C., Schuster T., Li G.X., Daniel P.T., Lü J. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol. Cancer Ther. 2006, 5:1873-1882.
13. Siddiqui I.A., Malik A., Adhami V.M., Asim M., Hafeez B.B., Sarfaraz S., Mukhtar H. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008, 27:2055-2063.
14. Prasad S., Yadav V.R., Kannappan R., Aggarwal B.B. Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. J. Biol. Chem. 2011, 286:5546-5557.
15. Voelkel-Johnson C. TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat. Rev. Urol. 2011, 8:417-427.
16. Szliszka E., Krol W. The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer prevention. Eur. J. Cancer Prev. 2011, 20:63-69.
17. Deepak M., Handa S.S. Antiinflammatory activity and chemical composition of extracts of Verbena officinalis. Phytother. Res. 2000, 14:463-465.
18. Huang M.T., Ho C.T., Wang Z.Y., Ferraro T., Lou Y.R., Stauber K., Ma W., Georgiadis C., Laskin J.D., Conney A.H. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and UA. Cancer Res. 1994, 54:701-708.
19. Ohigashi H., Takamura H., Koshimizu K., Tokuda H., Ito Y. Search for possible antitumor promoters by inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced Epstein-Barr virus activation; ursolic acid and oleanolic acid from an anti-inflammatory Chinese medicinal plant, Glechoma hederaceae L. Cancer Lett. 1986, 30:143-151.
20. Sohn K.H., Lee H.Y., Chung H.Y., Young H.S., Yi S.Y., Kim K.W. Anti-angiogenic activity of triterpene acids. Cancer Lett. 1995, 94:213-218.
21. Cha H.J., Bae S.K., Lee H.Y., Lee O.H., Sato H., Seiki M., Park B.C., Kim K.W. Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res. 1996, 56:2281-2284.
22. Lee H.Y., Chung H.Y., Kim K.H., Lee J.J., Kim K.W. Induction of differentiation in the cultured F9 teratocarcinoma stem cells by triterpene acids. J. Cancer Res. Clin. Oncol. 1994, 120:513-518.
23. Harmand P.O., Duval R., Liagre B., Jayat-Vignoles C., Beneytout J.L., Delage C., Simon A. Ursolic acid induces apoptosis through caspase-3 activation and cell cycle arrest in HaCat cells. Int. J. Oncol. 2003, 23:105-112. [23].
24. Tang C., Lu Y.H., Xie J.H., Wang F., Zou J.N., Yang J.S., Xing Y.Y., Xi T. Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis. Anticancer Drugs 2009, 20:249-258.
25. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999, 5:157-163.
26. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A., Behm F.G., Look A.T., Lahti J.M., Kidd V.J. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 2000, 6:529-535.
27. Deng Y., Lin Y., Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 2002, 16:33-45.
28. Martelli A.M., Tazzari P.L., Tabellini G., Bortul R., Billi A.M., Manzoli L., Ruggeri A., Conte R., Cocco L. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003, 17:1794-1805.
29. Nagane M., Cavenee W.K., Shiokawa Y. Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J. Neurosurg. 2007, 106:407-416.
30. Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C., McLaughlin M.M., Srinivasula S.M., Livi G.P., Marshall L.A., Alnemri E.S., Williams W.V., Doyle M.L. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 2000, 275:23319-23325.
31. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., Deforge L., Pai R., Hymowitz S.G., Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 2005, 280:2205-2212.
32. Szegezdi E., Cahill S., Meyer M., O'Dwyer M., Samali A. TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br. J. Cancer 2006, 94:398-406.
33. Shin S.W., Kim S.Y., Park J.-W. Autophagy inhibition enhances UA-induced apoptosis in PC3 cells. Biochim. Biophys. Acta 2012, 1823:451-457.
34. Jung E.M., Park J.W., Choi K.S., Park J.-W., Lee H.I., Lee K.S., Kwon T.K. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis 2006, 27:2008-2017.
35. Kim H., Kim E.H., Eom Y.W., Kim K.H., Kwon T.K., Lee S.J., Choi K.S. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res. 2006, 66:1740-1750.
36. Kim Y.H., Jung E.M., Lee T.J., Kim S.H., Choi Y.H., Park J.-W., Park J.W., Choi K.S., Kwon T.K. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic. Biol. Med. 2008, 44:1055-1068.
37. Takimoto R., el-Deiry W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000, 19:1735-1743.
38. Wu G.S., Kim K., el-Deiry W.S. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv. Exp. Med. Biol. 2000, 465:143-151.
39. Horinaka M., Yoshida T., Shiraishi T., Nakata S., Wakada M., Nakanishi R., Nishino H., Matsui H., Sakai T. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 2005, 24:7180-7189.
40. Yamaguchi H., Wang H.G. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J. Biol. Chem. 2004, 279:45495-45502.
41. Yoshida T., Shiraishi T., Nakata S., Horinaka M., Wakada M., Mizutani Y., Miki T., Sakai T. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 2005, 65:5662-5667.
42. Shiraishi T., Yoshida T., Nakata S., Horinaka M., Wakada M., Mizutani Y., Miki T., Sakai T. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. 2005, 65:6364-6370.